Norset (Mirtazapine)

Mirtazapine, the active ingredient in Norset, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It treats major depressive disorder in adult patients. GNH USA supplies Norset as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is a noradrenergic and specific serotonergic antidepressant that acts on mood‑regulating pathways. - Major depressive disorder: reduces depressive symptoms and improves mood in adult patients. - Treatment‑resistant depression: used as an adjunct when first‑line agents are insufficient. - Depressive episodes with prominent insomnia: improves sleep quality while alleviating depressive symptoms.

Mirtazapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Sedation or drowsiness - Increased appetite leading to weight gain - Dry mouth - Constipation - Dizziness - Somnolence

Serious or Rare Side Effects: - Agranulocytosis or neutropenia - Seizures - Severe hypotension - Hepatic dysfunction - Suicidal ideation, especially early in treatment - Severe allergic reactions such as Stevens‑Johnson syndrome

Before initiating therapy, clinicians should consider several safety measures. - Assess hepatic function: evaluate liver enzymes prior to starting treatment. - Monitor weight: watch for rapid weight gain or appetite changes. - Screen for suicidal thoughts: particularly during the first weeks of therapy. - Avoid abrupt discontinuation: taper the dose under medical supervision to reduce withdrawal risk. - Caution in elderly: increased sensitivity to sedation and orthostatic effects. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Mirtazapine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis when combined. - CNS depressants (e.g., benzodiazepines, barbiturates): additive sedation and respiratory depression. - Potent CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise mirtazapine plasma levels.

Moderate Interactions (Monitor Closely): - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): potential for serotonin syndrome. - Anticholinergic drugs: may exacerbate dry mouth and constipation. - Alcohol: enhances central nervous system depression and sedation.